NCT06793410View on ClinicalTrials.gov

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Recipients of Allogeneic Stem Cell TransplantationHPV (Human Papillomavirus)-AssociatedAcute Myeloid LeukaemiaMyelodysplastic SyndromeDiffuse Large B Cell Lymphoma (DLBCL)
Interventions
BIOLOGICAL

Early start post-transplant vaccination with Gardasil 9®

Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation.

BIOLOGICAL

Late post-transplant vaccination with Gardasil 9®

Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation.

Trial Locations (5)

17176

NOT_YET_RECRUITING

Karolinska University Hospital, Stockholm

22242

NOT_YET_RECRUITING

Skåne's University Hospital, Lund

41345

RECRUITING

Sahlgrenska University Hospital, Gothenburg

58185

RECRUITING

Linköping University Hospital, Linköping

75185

RECRUITING

Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Vastra Gotaland Region

OTHER_GOV

NCT06793410 - Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter